Literature DB >> 17274066

Improving AAV vector yield in insect cells by modulating the temperature after infection.

Marc G Aucoin1, Michel Perrier, Amine A Kamen.   

Abstract

Vectors based on adeno-associated viruses (AAV) are sought for therapeutic gene delivery because of their ability to transduce a variety of tissues with no significant immunological response. Production using the baculovirus expression vector (BEV)/insect cell system has the potential to meet the needs for pre-clinical and clinical trials. In this co-infection system, three baculoviruses are used to produce the AAV vector. A strategy aimed at increasing encapsidation/maturation of the viral vector involved varying the temperature over the course of the process. Cultures were subjected to temperature changes at various times pre- and post-infection (up to 24 h post-infection). It was found that raising the culture temperature to 30 degrees C at the time of infection nearly tripled the infectious titer. In fact, increasing the temperature to 30 degrees C at any time in the process investigated resulted in an increase in titer. Also, raising the culture to 33 degrees C or lowering the temperature to 24 degrees or 21 degrees C resulted in lower titers. The rise in infectious titer was also confirmed by an increase in DNase resistant particles (DRPs). Varying the temperature, however, did not affect the total amount of capsids significantly. Therefore increasing the culture temperature resulted in better encapsidation as determined by the ratio of capsids to DRPs to infectious particles. It is believed that an increase in early proteins and possibly a quicker cascade of baculovirus infection events resulted in this increased packaging efficiency. (c) 2007 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17274066     DOI: 10.1002/bit.21364

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  7 in total

1.  A Scalable and Accurate Method for Quantifying Vector Genomes of Recombinant Adeno-Associated Viruses in Crude Lysate.

Authors:  Jianzhong Ai; Raed Ibraheim; Phillip W L Tai; Guangping Gao
Journal:  Hum Gene Ther Methods       Date:  2017-04-13       Impact factor: 2.396

2.  Filling Adeno-Associated Virus Capsids: Estimating Success by Cryo-Electron Microscopy.

Authors:  Suriyasri Subramanian; Anna C Maurer; Carol M Bator; Alexander M Makhov; James F Conway; Kevin B Turner; James H Marden; Luk H Vandenberghe; Susan L Hafenstein
Journal:  Hum Gene Ther       Date:  2019-11-14       Impact factor: 5.695

3.  Scalable Process for High-Yield Production of PfCyRPA Using Insect Cells for Inclusion in a Malaria Virosome-Based Vaccine Candidate.

Authors:  Bárbara Fernandes; Marcos Sousa; Rute Castro; Anja Schäfer; Julia Hauser; Kai Schulze; Mario Amacker; Marco Tamborrini; Gerd Pluschke; Paula M Alves; Sylvain Fleury; António Roldão
Journal:  Front Bioeng Biotechnol       Date:  2022-05-20

Review 4.  Pharmacology of Recombinant Adeno-associated Virus Production.

Authors:  Magalie Penaud-Budloo; Achille François; Nathalie Clément; Eduard Ayuso
Journal:  Mol Ther Methods Clin Dev       Date:  2018-01-08       Impact factor: 6.698

Review 5.  Co-expression vs. co-infection using baculovirus expression vectors in insect cell culture: Benefits and drawbacks.

Authors:  Stanislav Sokolenko; Steve George; Andreas Wagner; Anup Tuladhar; Jonas M S Andrich; Marc G Aucoin
Journal:  Biotechnol Adv       Date:  2012-01-28       Impact factor: 14.227

6.  High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells.

Authors:  Yixiao Wu; Thomas Bissinger; Yvonne Genzel; Xuping Liu; Udo Reichl; Wen-Song Tan
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-30       Impact factor: 4.813

7.  Performance of Cardiotropic rAAV Vectors Is Dependent on Production Method.

Authors:  Renuka Rao; Melad Farraha; Grant J Logan; Sindhu Igoor; Cindy Y Kok; James J H Chong; Ian E Alexander; Eddy Kizana
Journal:  Viruses       Date:  2022-07-26       Impact factor: 5.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.